For the year ending 2025-12-31, NEPH had $1,640K increase in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Total net revenues | 18,789 |
| Cost of goods sold | 7,164 |
| Gross margin | 11,625 |
| Research and development | 1,339 |
| Selling, general and administrative | 9,000 |
| Other operating expenses | 140 |
| Total operating expenses | 10,479 |
| Operating income | 1,146 |
| Total other income | 60 |
| Income tax expense | 12 |
| Net income | 1,194 |
| Depreciation of property and equipment | 55 |
| Amortization of intangible assets, license and supply agreement and finance lease right-of-use asset | 84 |
| Stock-based compensation | 296 |
| Inventory impairments and writeoffs | 68 |
| Change in right-of-use asset | 356 |
| (gain) or loss on foreign currency transactions | -5 |
| Accounts receivable | 633 |
| Inventory | 685 |
| Prepaid expenses and other current assets | 35 |
| Accounts payable | 259 |
| Accrued expenses | 1,024 |
| Lease liabilities | -343 |
| Net cash provided by (used in) operating activities | 1,645 |
| Net cash used in investing activities | 0 |
| Principal payments on finance lease liability | 5 |
| Net cash used in financing activities | -5 |
| Net increase (decrease) in cash and cash equivalents | 1,640 |
| Cash and cash equivalents, beginning of year | 3,760 |
| Cash and cash equivalents, end of year | 5,400 |
NEPHROS INC (NEPH)
NEPHROS INC (NEPH)